Company: PTPI
Filing Date: 2025-03-14
Form Type: PRER14A
Source: 0001104659-25-024012
Chunk: 3

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-14
Form: PRER14A
Chunk 3
---
2025
PLACE: www.virtualshareholdermeeting.com/PTPI2025SM

Purposes:

| 1. | To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock, par value $0.0001 per share (the “Common Stock”) underlying the Series A warrants (the “Series A Warrants”) and Series B warrants (the “Series B Warrants” and, together with the Series A Warrants, the “Series Warrants”), including by operation of certain anti-dilution provisions contained therein,   issued by us in a public offering transaction (the “Offering”) on February 19, 2025 (including an aggregate of approximately 1,064,846,416.38 shares of Common Stock issuable upon exercise of the Series Warrants, which consists of (i) an aggregate of approximately 81,911,262.80 shares of Common Stock issuable upon exercise of 40,000,000 Series A Warrants issued in the Offering (assuming the full exercise of the Series A Warrants at an exercise price equal to the floor price of $0.0586) and (ii) an aggregate of approximately 982,935,153.58 shares of Common Stock issuable upon exercise of 40,000,000 Series B Warrants issued in the Offering (assuming (x) the full exercise of the Series B Warrants at an exercise price equal to the floor price of $0.0586 and (y) all the Series B Warrants are exercised on the “zero exercise price” basis) (“Proposal 1” or, the “Issuance Proposal”); |

| 2. | To approve an amendment to our Amended and Restated Certificate of                                                                       
 Incorporation, as amended (the “Charter”) to effect, at the discretion of the Board but prior to the one-year anniversary                
 of the date on which the reverse stock split is approved by the Company’s stockholders at the Special Meeting, a reverse stock split     
 of all of the outstanding shares of our Common Stock at a ratio in the range of 1-for-250 to 1-for-500, with such ratio to be determined 
 by the board of directors (the “Board”) of the Company in its discretion and included in a public announcement (“Proposal                
 2” or, the “Reverse Stock Split Proposal”);                                                                                              |

| 3. | To approve the Third Amendment to the